Myriad Genetics/$MYGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Myriad Genetics

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Ticker

$MYGN
Primary listing

Industry

Biotechnology

Employees

2,700

ISIN

US62855J1043

Myriad Genetics Metrics

BasicAdvanced
$527M
-
-$1.12
2.02
-

What the Analysts think about Myriad Genetics

Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.

Bulls say / Bears say

Myriad Genetics reported a 15% year-over-year revenue growth in Q2 2024, driven by significant increases in Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%) segments. (finance.yahoo.com)
The company has entered strategic partnerships, including collaborations with GlaxoSmithKline and QIAGEN, to enhance diagnostic testing capabilities and expand market reach. (nasdaq.com)
Myriad Genetics is investing in lab technologies and integrating digital capabilities, such as EMR system integrations, to enhance operational efficiency and prepare for the launch of new products like the Precise MRD test for breast cancer in 2026. (investing.com)
Insiders, including the CEO, sold approximately $6.5 million worth of stock over the past year, which may signal potential concerns about the company's future performance. (simplywall.st)
UnitedHealthcare's decision to discontinue coverage of Myriad's GeneSight test in 2025 is expected to impact revenue by approximately $45 million, posing a significant financial challenge. (financialcontent.com)
Morgan Stanley has reduced its stock target for Myriad Genetics from $21 to $16, reflecting concerns about the company's future growth prospects. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Myriad Genetics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Myriad Genetics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MYGN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs